Role of zinc oxide nanoparticles supplementation on alleviate side effects of cisplatin induced cardiotoxicity in rats

Al-lbban, A. M.

doi:10.1590/1519-6984.287764

home Sumário navigate_before Anterior Atual Seguinte navigate_next

home Sumário

Original Article • Braz. J. Biol. 84 • 2024 • https://doi.org/10.1590/1519-6984.287764 linkcopy

Role of zinc oxide nanoparticles supplementation on alleviate side effects of cisplatin induced cardiotoxicity in rats

Papel da suplementação com nanopartículas de óxido de zinco no alívio dos efeitos colaterais da cardiotoxicidade induzida pela cisplatina em ratos

Authorship SCIMAGO INSTITUTIONS RANKINGS

Abstract

Cisplatin is one of the most potent chemotherapeutics for treating a wide range of tumor forms. Its use is severely limited due to cause cardiotoxicity. The goal of this investigate estimated the proactive effect of ZnONPs against cardiotoxicity induced by cisplatin (CP). The rats were classed as control-positive (group two), and different groups from third to seventh were given one milliliter of individually dosed ZnONPs at 10, 20, 30, 40, and 50 mg/kg daily and compared with control negative group (group one). Atherogenic indices (AC, CRR, and AI), lipid peroxidation, heart tissue antioxidant enzymes, cytokines, and specific serum biomarkers lipid profiles (TC, TG, HDL, and LDL), and kidney functions were assessed in serum at the ending of the biological experimental. Findings were in view that these parameters improved gradually when the doses of ZnONPs in the various rat groups were increased to 50 mg/kg/day/bw. Measurements of pro-inflammatory, antioxidant, and oxidant biomarkers in heart tissue also showed that, at a dose of 50 mg/kg/day, the various rat groups progressively recovered to a level equivalent to that of the healthy control group. This clarifies why ZnONPs guard against heart tissue injury. It was determined that ZnONPs, with a more marked improvement, considerably reduced oxidative stress, suppressed inflammation, and inhibited apoptosis, thereby improving cisplatin-induced heart damage.

Keywords:
zinc oxide; nanoparticles; cisplatin; cardiotoxicity; rats

Treatments	Triglycerides mg/dL	Total cholesterol mg/dL	LDL mg/dL	HDL mg/dL
Negative group	80.23 ± 2.25^f	140.85 ± 5.18^f	37.62 ± 1.54^f	60.41 ± 1.57^a
Positive control	151.92 ± 4.73^a	210.76 ± 5.62^a	100.43 ± 2.53^a	30.97 ± 1.09^e
Group 3 (10 mg/kg/bw)	138.23 ± 3.28^b	197.65 ± 5.56^b	88.38 ± 2.66^b	36.34 ± 1.14^d
Group 4 (20 mg/kg/bw)	124.54 ± 3.11^c	184.54 ± 5.38^c	75.88 ± 2.84^c	41.67 ± 1.59^c
Group 5 (30 mg/kg/bw)	110.85 ± 2.48^d	171.43 ± 4.49^d	63.83 ± 2.39^d	47.00 ± 2.01^bc
Group 6 (40 mg/kg/bw)	97.16 ± 2.15^e	158.32 ± 4.67^e	51.78 ± 1.81^e	52.33 ± 2.27^b
Group 7 (50 mg/kg/bw)	83.45 ± 2.13^f	145.20 ± 3.61^f	40.17 ± 1.78^f	57.82 ± 2.49^ab

Treatments	Atherogenic coefficient (AC)	Cardiac risk ratio (CRR)	Atherogenic index (AI)
Negative group	0.623 ± 0.07^e	2.331 ± 0.06^e	0.123 ± 0.02^e
Positive control	3.242 ± 0.18^a	6.805 ± 0.26^a	0.691 ± 0.04^a
Group 3 (10 mg/kg/bw)	2.432 ± 0.09^b	5.438 ± 0.12^b	0.579 ± 0.04^b
Group 4 (20 mg/kg/bw)	1.821 ± 0.04^c	4.428 ± 0.18^c	0.475 ± 0.03^c
Group 5 (30 mg/kg/bw)	1.358 ± 0.03^cd	3.647 ± 0.16^cd	0.363 ± 0.02^cd
Group 6 (40 mg/kg/bw)	0.989 ± 0.07^d	3.025 ± 0.14^d	0.268 ± 0.01^d
Group 7 (50 mg/kg/bw)	0.694 ± 0.05^e	2.511 ± 0.12^e	0.159 ± 0.01^e

Treatments	Urea (mg/dl)	Creatinine (mg/dl)	Uric acid (mg/dl)	Bilirubin mg/dl	Albumin (mg/dl)	Total protein (mg/dl)
Negative group	28.35 ± 1.14^e	0.68 ± 0.01^e	3.11 ± 0.14^e	0.56 ± 0.01^e	6.24 ± 0.22^a	10.22 ± 0.83^a
Positive control	65.68 ± 5.32^a	1.15 ± 0.02^a	6.92 ± 0.15^a	0.98 ± 0.02^a	2.12 ± 0.12^c	4.94 ± 0.17^e
Group 3 (10 mg/kg/bw)	60.29 ± 4.38^a	1.03 ± 0.02^a	6.31 ± 0.12^a	0.91 ± 0.02^a	2.84 ± 0.11^a	5.23 ± 0.15^e
Group 4 (20 mg/kg/bw)	55.17 ± 4.36^b	0.92 ± 0.04^b	5.92 ± 0.43^b	0.81 ± 0.03^b	3.45 ± 0.14^b	6.11 ± 0.23^d
Group 5 (30 mg/kg/bw)	44.68 ± 3.28^c	0.83 ± 0.04^c	5.33 ± 0.24^c	0.73 ± 0.03^c	4.67 ± 0.16^a	7.35 ± 0.31^c
Group 6 (40 mg/kg/bw)	36.4 ± 2.66^d	0.71 ± 0.03^d	4.43 ± 0.25^d	0.61 ± 0.02^d	5.65 ± 0.23^a	8.92 ± 0.57^b
Group 7 (50 mg/kg/bw)	29.56 ± 1.32^e	0.65 ± 0.01^e	3.05 ± 0.13^e	0.54 ± 0.02^e	6.11 ± 0.23^a	10.04 ± 0.79^a

Treatments	CAT (U/L)	SOD (U/L)	GPX (U/L)	GSH (U/L)	MDA (nmol/mL)
Negative group	7.23 ± 0.27^a	13.75 ± 0.77^a	50.23 ± 4.31^a	24.25 ± 1.67^a	180.34 ± 3.44^a
Positive control	4.12 ± 0.19^d	6.48 ± 0.47^e	22.36 ± 1.0^d	13.89 ± 0.55^d	384.39 ± 3.59^d
Group 3 (10 mg/kg/bw)	4.74 ± 0.34^d	7.92 ± 0.62^d	27.91 ±1.73^d	15.82 ± 0.75^cd	344.47 ± 4.36^c
Group 4 (20 mg/kg/bw)	5.36 ± 0.63^c	9.36 ± 0.86^c	33.46 ± 2.35^c	17.75 ± 0.94^c	304.55 ± 4.29^c
Group 5 (30 mg/kg/bw)	5.98 ± 0.67^c	10.80 ± 0.84^bc	39.01 ± 2.47^c	19.69 ± 1.21^b	264.62 ± 5.17^b
Group 6 (40 mg/kg/bw)	6.60 ± 0.71^b	12.24 ± 0.91^b	44.56 ± 3.86^b	21.61 ± 1.08^ab	224.71 ± 4.56^ab
Group 7 (50 mg/kg/bw)	7.00 ± 0.31^a	13.51 ± 0.84^a	49.98 ± 2.39^a	23.54 ± 1.78^a	184.10 ± 3.48^a

Treatments	IL-1β (pg/mL)	TNF-α (pg/mL)	CK-MB (U/L)	LDH (U/L)
Negative group	13.16 ± 1.11^e	19.31 ± 1.42^d	541 ± 8.21^d	889 ± 9.23^f
Positive control	52.19 ± 1.30 ^a	45.51 ± 1.22 ^a	742 ± 8.43^a	1347 ± 8.15^a
Group 3 (10 mg/kg/bw)	44.31 ± 1.51^ab	40.29 ± 1.24^a	701 ± 9.25^a	1254 ± 10.76^b
Group 4 (20 mg/kg/bw)	36.63 ± 1.36^b	35.17 ± 1.35^b	660 ± 7.29^ab	1161 ± 9.54^c
Group 5 (30 mg/kg/bw)	28.55 ± 1.24^c	30.05 ± 1.51^bc	619 ± 7.15^b	1068 ± 8.27^d
Group 6 (40 mg/kg/bw)	21.17 ± 1.14^d	24.63 ± 1.27^c	578 ± 6.38^c	979 ± 6.28^e
Group 7 (50 mg/kg/bw)	12.30 ± 0.11^e	18.53 ± 1.41^d	530 ± 5.11^d	872 ± 7.68^f

vertical_align_top show_chart

more_horiz close
- image
- translate
- link
- article
- vertical_align_top
- file_download
- show_chart
- image
- translate
- link
- article

location_on

Instituto Internacional de Ecologia R. Bento Carlos, 750, 13560-660 São Carlos SP - Brasil, Tel. e Fax: (55 16) 3362-5400 - São Carlos - SP - Brazil
E-mail: bjb@bjb.com.br

rss_feed Acompanhe os números deste periódico no seu leitor de RSS

[1] Values ± SD in the columns are statistically various when P ≤ 0.05.